key: cord-0861000-mj0jbgcr
authors: Tanaka, Shiho; Nelson, Gard; Olson, Anders; Buzko, Oleksandr; Higashide, Wendy; Shin, Annie; Gonzales, Marcos; Taft, Justin; Patel, Roosheel; Buta, Sofija; Martin-Fernandez, Marta; Bogunovic, Dusan; Spilman, Patricia; Niazi, Kayvan; Rabizadeh, Shahrooz; Soon-Shiong, Patrick
title: A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants
date: 2021-03-09
journal: bioRxiv
DOI: 10.1101/2021.03.09.434641
sha: 63ba575c137ae6727393229670732ea16f556643
doc_id: 861000
cord_uid: mj0jbgcr

The highly-transmissible SARS-CoV-2 variants now replacing the first wave strain pose an increased threat to human health by their ability, in some instances, to escape existing humoral protection conferred by previous infection, neutralizing antibodies, and possibly vaccination. Thus, other therapeutic options are necessary. One such therapeutic option that leverages SARS-CoV-2 initiation of infection by binding of its spike receptor binding domain (S RBD) to surface-expressed host cell angiotensin-converting enzyme 2 (ACE2) is an ACE2 ‘decoy’ that would trap the virus by competitive binding and thus inhibit propagation of infection. Here, we used Molecular Dynamic (MD) simulations to predict ACE2 mutations that might increase its affinity for S RBD and screened these candidates for binding affinity in vitro. A double mutant ACE2(T27Y/H34A)-IgG1FC fusion protein was found to have very high affinity for S RBD and to show greater neutralization of SARS-CoV-2 in a live virus assay as compared to wild type ACE2. We further modified the double mutant ACE2 decoy by addition of an H374N mutation to inhibit ACE2 enzymatic activity while maintaining high S RBD affinity. We then confirmed the potential efficacy of our ACE2(T27Y/H34A/H374N)-IgG1FC Triple Decoy against S RBD expressing variant-associated E484K, K417N, N501Y, and L452R mutations and found that our ACE2 Triple Decoy not only maintains its high affinity for S RBD expressing these mutations, but shows enhanced affinity for S RBD expressing the N501Y or L452R mutations and the highest affinity for S RBD expressing both the E484K and N501Y mutations. The ACE2 Triple Decoy also demonstrates the ability to compete with wild type ACE2 in the cPass™ surrogate virus neutralization in the presence of S RBD with these mutations. Additional MD simulation of ACE2 WT and decoy interactions with S RBD WT or B.1.351 variant sequence S RBD provides insight into the enhanced affinity of the ACE2 decoy for S RBD and reveals its potential as a tool to predict affinity and inform therapeutic design. The ACE2 Triple Decoy is now undergoing continued assessment, including expression by a human adenovirus serotype 5 (hAd5) construct to facilitate delivery in vivo. Summary sentence An ACE2(N27Y/H34A/H374N)-IgG1FC fusion protein decoy sustains high affinity to all SARS-CoV-2 spike receptor binding domain (RBD) protein variants tested, shows enhanced affinity for the N501Y and L452R variants, and the highest affinity for combined N501Y and E484K variants.

SARS-CoV-2 variants have rapidly swept the globe 1-3 and very recent investigations reveal 51 that several of these variants have shown the ability to escape neutralization by convalescent 52 antibodies in recovered COVID-19 patients 4 and recombinant neutralizing antibodies (nAbs) 53 developed as therapeutics. 5, 6 There are also fears that current vaccines may not be as effective 54

against some of the variants and early evidence suggests that for some vaccines, this risk may exist. 55 7,8 The latter is a particular concern, as the massive vaccine efforts currently underway employ 56 vaccines designed to elicit immune responses against first-wave sequence SARS-CoV-2 spike (S) 57 protein and specifically the S receptor binding domain (S RBD) that binds to angiotensin-58 converting enzyme 2 (ACE2) on the surface of human cells in the airway and gut that initiates 59 viral entry and infection. 9-12 While one response to the threat of loss of vaccine efficacy might be 60 to continually re-design vaccines to target specific new variants, this would be an ongoing game 61 of catch-up because it can be expected that further novel variants will emerge, particularly since 62 several recent reports have shown that antibodies elicited by infection and vaccination act as 63 evolutionary forces that result in the predominance of viral variants that escape these immune 64 defenses. 13,14 65

While efforts to adapt vaccines should be encouraged, in parallel, new therapeutic approaches 66

to neutralize viral infection that are not undermined by the presence of mutations should be 67

To address the need for a therapeutic and potentially prophylactic approach that has a low 69 likelihood of being adversely affected by variant mutations, we have designed and tested ACE2 70 'decoys' that leverage the binding of the S RBD to ACE2. This is an approach that is also being 71 pursued by others using a variety of fusion proteins and delivery methods. [15] [16] [17] [18] Our ACE2 decoys 72 under development are recombinant ACE2-IgG1FC or -IgAFC fusion proteins, with the ACE2 73 sequence optimized for binding affinity to S RBD. The ACE2 decoy would be given to a patient 74 infected with SARS-CoV-2, act to prevent binding of virus to host cell ACE2 by competing with 75 endogenous ACE2 for spike binding, and allow clearance of the virus. 19-21 76

To successfully compete, an efficacious ACE2 decoy would ideally have significantly higher 77 affinity for S RBD than endogenous, host-cell expressed ACE2. To identify ACE2 mutations with 78 a high probability of increasing affinity, we utilized our in silico Molecular Dynamic (MD) 79 simulation capabilities as described in Nelson et al. 22 "Millisecond-scale molecular dynamics 80 simulation of spike RBD structure reveals evolutionary adaption of SARS-CoV-2 to stably bind 81 ACE2" wherein we reported on our identification of regions of high affinity interaction between 82 ACE2 and S RBD based on previously reported S RBD structures. 23,24 83

Because the ACE2 decoy concept is based on interaction of ACE2 with S RBD, its binding 84 affinity and thus efficacy may also be vulnerable to changes in the SARS-CoV-2 S RBD sequence. 85

We therefore assessed the affinity of our ACE2 decoy, as compared to wild type (WT) ACE2, for 86 S RBD with a variety of single or multiple mutations associated with the currently predominant 87 variants, including the B. In initial studies to design an ACE2 decoy, we determined the affinity of both recombinant 98 

Based on MD simulation-based predictions of mutations that may confer enhanced binding 114 affinity of ACE2 for S RBD, several ACE2 variants were tested for binding affinity as ACE2-115 The ACE2(T27Y/H34A)-IgG1FC double decoy was compared to an ACE2(WT)-IgG1FC 122 decoy in a live SARS-CoV-2 virus assay using Vero E6 cells. As shown in Figure 2E , the double 123 mutant ACE2 decoy showed ~15-fold improvement in SARS-CoV-2 neutralization capability 124 compared to the wild type ACE2 Decoy. Addition of an H374N mutation inhibits ACE2 enzyme activity 148

In addition to enhanced affinity for competitive binding of S RBD, we wanted to inhibit the 149 enzymatic activity of ACE2. 28 Angiotensin-converting enzyme 2 has an important role in 150 homeostasis of the renin-angiotensin system 29-31 by cleavage of its substrate angiotensin 1-9 32 151 and its activity affects a variety of systems. Addition of enzymatically active recombinant ACE2 152

to the system presents a high risk of unwanted side effects and since S RBD binding, but not 153 substrate cleavage activity, is the key function for the ACE2 decoy, we tested a variety of mutations 154 predicted to inhibit ACE2 enzymatic activity with a low likelihood of affecting S RBD binding 155

All of the ACE2 mutations (R273Q, R273K, R273L, H345A, H505L, H374N, or H378N) 157 predicted or known to inhibit ACE2 enzymatic activity 33,34 did inhibit this activity in the assay 158 Supplementary Fig. S1 ). ACE2 triple mutant decoys comprising the S 159 RBD binding affinity-enhancing T27Y/H34A mutations and the enzymatic activity-inhibiting 160 mutations were produced and binding affinity assessed. Of the triple mutants, those with either the 161 R273K or H374N mutations showed the highest S RBD affinity (Supplementary Table S1 ). 162

The final ACE2 Triple Decoy chosen for further testing was ACE2 (T27Y/H34A/H374N)-163

IgG1FC due to its more favorably biophysical characteristics as compared to an R273K-containing 164 triple mutant, including a lower propensity to aggregate and a higher titer ( Supplementary Fig. S2  165 and Table S2) . The ACE2 Triple Decoy showed higher binding affinity to all S RBD sequences as compared 173

to the wild type ACE2 decoy. As compared to the ACE2 Triple Decoy binding affinity for S RBD 174 WT, affinities for S RBD E484K/N501Y, N501Y alone and L452R were higher; affinities for S 175 RBD E484K, K417N/N501Y, N417N/E484K/N501Y, K417K/E484K, and K417N were lower. 176

Findings were similar with the wild type ACE2 decoy, with the highest affinity seen for 177 E484K/N501Y and N501Y alone, and the lowest affinities for variants expressing K417N. N501Y 178 and L452R showed ~2-3 fold increase in binding affinity for both wild type ACE2 decoy and 179 ACE2 Triple Decoy. E484K alone did not affect binding affinity to ACE2. K417N weakened 180 binding affinity for ACE2 (WT) and triple decoys, but affinity was restored when combined with 181 N501Y. The E484K, K417N and N501Y mutations occur together in the B.1.351 strain, whereas 182 L452R alone is found in CAL.20.C, therefore assessment of ACE2 WT binding to these variants 183 as they occur in nature is most physiologically relevant (Supplementary Fig. S3 and Table S3) . The MD simulation data presented here used to guide design of the ACE2 Triple Decoy and 258

to predict affinities of the decoy as compared to ACE2 WT for a series of variants reveal again the 259 merits of such simulations as a tool to inform therapeutic design. 260

Interestingly, widespread use of an ACE2 decoy has the potential itself to act as an 261 evolutionary force; however, an ACE2 decoy largely recognizes the same residues as endogenous 262 ACE2 and therefore it is highly unlikely a SARS-CoV-2 variant could emerge that 'escapes' the 263 decoy yet still binds to endogenous ACE2. This phenomenon along with limited use of a decoy 264 for therapy as compared to the spread of virus in a large population with opportunity for selection, 265 makes the decoy approach less vulnerable to loss of efficacy due to mutation of the virus. 266

The enhanced binding affinity of our Triple Mutant ACE2 Decoy to S RBD with the variant 267 mutations tested here supports continued pursuit of this therapeutic approach and further provides 268 hope that even should the efficacy of vaccines currently in distribution or therapeutic neutralizing 269 antibodies raised against WT spike be lessened by these variants, there will be an alternative 270 therapeutic approach to successfully treat COVID-19 disease. 271

In our next steps in development of the ACE2 Triple Decoy, we will address the challenge of 272 

The WT-ACE2/RBD complex was built from the cryo-EM structure, PDB 6M17 of full-425 length human ACE2 in the presence of the neutral amino acid transported B 0 AT1 with the S RBD 426 as shown in Yan et al. 47 using RBD residues 336-518 and ACE2 residues 21-614. ACE2 residues 427 27 and 34 were mutated to tyrosine and alanine, respectively. The final simulation system was 428 built using the Amber ff14SB force field 48 . The RISM program from AmberTools19 49 was used 429 to determine optimal locations for water molecules in direct contact with the proteins. Bulk waters 430 were added to create a sufficient octahedral water box and sodium ions were added at random 431 locations to neutralize the system. After introducing mutations at the relevant residues, the same 432 procedure was used to generate the other three systems. 433

Simulation 434

Ten copies of each RBD/ACE2 complex were minimized, equilibrated and simulated. 435

Minimization occurred in two phases. During the first, the protein and RISM-placed waters were 436 restrained. The second phase minimized the entire system. Dynamics then began and the 437 temperature was ramped from 0 to 300K while restraining the protein and RISM-placed waters. 438

All dynamics used SHAKE restraints on hydrogen-containing bonds and a 2 fs timestep. All 439 restraints were then released and the system was equilibrated in the NPT ensemble for 2 ns. Finally, 440 each system was equilibrated in the NVT ensemble for 100 ns. were pelleted by centrifugation at 1,400 rpm for 10 min, re-suspended in 10 mL of electroporation 517 buffer, and re-pelleted at 1,400 rpm for 5 min. The cell pellet was resuspended at a density of 2 x 518 IgG1Fc or ACE2(WT)-IgA sequence at a concentration of 150 µg/mL, and transfected using OC-520 400 processing assemblies in a Maxcyte® ExPERT ATx Transfection System. Transfected cells 521

were incubated for 30 min at 37 ℃, 5% CO2 and then resuspended in Efficient Feed A Cocktail 522 (CHO-CD EfficientFeed™ A + 0.2% Pluronic F-68 + 1% HT Supplement + 1% L-glutamine) at 523 a density of ~4-6 x 10 6 cells/mL. This cell culture was incubated at 37 ℃ with 5% CO2 and 125 524 rpm rotation overnight, 1 mM sodium buryrate was added, and the culture was further incubated 525 at 32 ℃ with 3% CO2 and 125 rpm for 13 more days; during this incubation period, Maxcyte® 526

Feed Cocktail (13.9% CD Hydrolysate, 69.5% CHO CD EfficientFeed™ A, 6.2% Glucose, 6.9% 527 FunctionMax™ Titer Enhancer, 3.5% L-Glutamine) was added at 10% of the culture volume on 528

Days 3 and Day 8. FectoPRO® transfection reagent (PolyPlus-transfection®) was mixed with 5 mL of 15 µg/mL 535 pcDNA3 plasmid DNA in CD-CHO media and incubated for 10 min at room temperature. The 536 DNA/transfection reagent mixture was added to 45 mL of CHO-S culture and incubated at 37 ℃ 537 with 5% CO2 and 125 rpm rotation. On Day 3, 50 mL of the CD-CHO media supplemented with 538 8 mM L-glutamine was added and the culture incubated for an additional 4 days. 539

For transient expression of RBD wild-type and RBD mutants, HEK-293T cells were cultured 541 and incubated at 37℃ with 5% CO2. Plasmids harboring RBD constructs were mixed with 542 lipofectamine with 1:1 (v:v) and incubated for 20 min at room temperature. The mixture was then 543 added to cultures and incubated for 3-4 days. 544

The MaxCyte® or FectoPRO® transfection cell culture medium was centrifuged and filtered 546 through a 0.22 µm filter to remove cells and debris, then loaded onto a HiTrap™ MabSelect 547

SuRe™ column on the AKTA Pure system pre-equilibrated with 10 mM Na Phosphate and 150 548 mM NaCl at pH 7.0. After loading, the column was washed with 10 column volumes of the same 549 buffer. The protein was eluted with 100 mM sodium acetate, pH 3.6, then immediately neutralized 550 using 2 M Tris pH 8.0. The elution fractions were pooled and dialyzed into 10 mM Hepes and 150 551 mM sodium chloride at pH 7.4. 552

The MaxCyte® transfection cell culture medium was centrifuged and filtered through a 0.22 554 µm filter to remove cells and debris, then loaded to a gravity column packed with CaptureSelect® 555

IgA resins (Thermo Fisher) pre-equilibrated with 10 mM Na Phosphate and 150 mM NaCl at pH 556 7.0. After loading, the column was washed with 10 column volumes of the same buffer. The protein 557 was eluted with 100 mM sodium acetate, pH 3.0, then immediately neutralized using 2 M Tris, pH 558 8.0. The elution fractions were pooled and dialyzed into 10 mM Hepes and 150 mM sodium 559 chloride, pH 7.4. 560

The Lipofectamine transfection cell culture medium was centrifuged and filtered through a 562 0.22 µm filter to remove cells and debris. A buffer of 50 mM Tris, 100 mM sodium chloride, and 563 10 mM imidazole was added to the supernatant then loaded to a gravity column packed with Ni-564 NTA resins (Qiagen) pre-equilibrated with 20 mM Tris, 300 mM sodium chloride, and 10 mM 565 imidazole, pH8.0. After loading, the column was washed with 10 column volumes of the same 566 buffer. The protein was eluted with 20 mM Tris, 150 mM sodium chloride, and 300 mM imidazole. 567

The elution fractions were pooled and dialyzed into 10 mM HEPES and 150 mM sodium chloride, 568 pH 7.4. 569

The running buffer in all experiments was 10 mM HEPES, 150 mM NaCl, pH 7.4, with 0.02% 571 tween 20, and 0.1% BSA unless otherwise indicated. For the determination of 1:1 binding affinity 572 of ACE2 Decoys against SARS-CoV2 RBD wild-type and mutants, ACE2 Decoys were 573 immobilized on an AHC sensor (Sartorius Corporation) and an RBD concentration series of 200, 574 100, 50, 25, 12.5, 6.25, 3.125 nM was used to determine the dissociation coefficient (KD). For 575 determining ACE2 Decoy binding affinity with avidity, biotinylated RBD was immobilized on 576 streptavidin (SA) or high-precision SA (SAX) sensors, and the ACE2 Decoy concentration series 577 of 200, 100, 50, 25, 12.5, 6.25, 3.125 nM was used to determine KD. 578 cPass™ 36 surrogate SARS-CoV-2 neutralization assay 579

High BIND 96-well ELISA plates (Corning #3369) were coated with 50 ng/well ACE2 wild 580 type decoy overnight at 4℃. After the antigen solution was removed, each well was blocked with 581 150 µL of 5% BSA/PBS for 1-2 hours at room temperature with shaking. During the blocking 582 step, 40 µL of 50 nM RBD and RBD variants were mixed with 40 µL of 25 µg/mL of ACE2 decoy 583 were mixed in a 96-well plate and incubated at room temperature for 30 min with shaking. After 584 blocking, the plate was then washed 3 times with 250 µL of PBS with 0.05% Tween 20 (PBS-T). 585

To each well, 30 µL of 1:1667 diluted mouse anti-His, HRP and 60 µL of RBD/ACE2 decoy (or 586 a no decoy control) were added and incubated at room temperature for 30 min. The plated was 587 washed once with 250 µL of PBS-T. To develop the signal, 50 µL of TMB solution was added 588

Assay for ACE2 enzymatic activity 615

Enzymatic activity ACE2 decoys expressing a variety of mutations -R273Q, R273K, 616 R273L, H245A, H505L, H374N, and H378N -selected to inhibit activity in combination with 617 the S RBD affinity-enhancing mutations T27Y and H34A were assessed in the FRET based 618 ACE2 activity assay. 619 620

As shown in Figure S1 , wild type (WT) and the T27Y/H34A mutations had similar ACE2 To choose which of these activity-inhibiting mutations would be used in combination with 631 the two affinity-enhancing mutations, we compared BLI kinetic analysis of S RBD binding for 632 each. Of the triple mutants, the ones expressing R273K or H374N had the lowest dissociation 633 coefficient (KD), that is, highest affinity binding. 634

The T27Y/H34A/H374N triple mutant was chosen for further testing because it showed 635 better biophysical properties, including a lower propensity to aggregate, higher titer/better Tm as 636

compared to the decoy with the R273K substitution. 637 638 639 Titer analysis for the triple decoys is shown below in Fig. S2 and Table S2 . 

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing 393 viruses and inflammatory cytokines

Rapid generation of circulating 396 and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of 397 SARS-CoV-2. bioRxiv

Enhanced SARS-CoV-2 neutralization by dimeric IgA

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both 401 Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and 402 Neutralizing Antibody Responses

Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 405 Challenge by Antibody Plus Th1 Dominant N-and S-Specific T-Cell Responses to 406

Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an 407 NHP Study. bioRxiv

Structural basis for the recognition of SARS-CoV-2 by full-length human 409 ACE2

ff14SB: Improving the Accuracy of Protein Side Chain and Backbone 411 Parameters from ff99SB

University of California

Well-tempered metadynamics: a smoothly 415 converging and tunable free-energy method

Potential of Mean Force Calculations: A 418 Multiple-Walker Adaptive Biasing Force Approach

and incubated at room temperature in dark for 30 min, followed by addition of 50 µL of 2M sulfuric 589 acid; absorbance was the read at 450nm. The percent inhibition was calculated using (1-A450

PshA1 digestion fragment of ACE2-IgG1FC plasmid, and 2) a 0.773 kb SOE product of primers 489 5MutF and 5MutR of two PCR products. The first PCR is a 0.154 kb amplification of plasmid SR9 490 with primers 5MutF and ACE2T27YR). The second PCR products is a 0.642 kb amplification of 491 plasmid SR9 with primers ACE2T27YF and 5MutR. 492Most of the triple mutants were created by Gibson Assembly of three fragments: 1) the vector 493 backbone from a 7.168 kb NheI-XhoI fragment of pWT35, 2) IgG1FC from a 0.701 kb PCR 494 amplification of pXL159 with primers WH1045 and WH1046, and 3) the ACE2 variant from a